8-K Announcements
6Material company update
May 15, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Apr 7, 2026·SEC
Insmed Incorporated(INSM)Earnings, Financials & Key Ratios
INSM•NASDAQ
Price updated Jun 19, 2026
AboutInsmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.Show more
- Revenue$606M+66.7%
- EBITDA-$1.16B-33.8%
- Net Income-$1.28B-39.7%
- EPS (Diluted)-6.41-15.1%
- Gross Margin79.41%+3.9%
- EBITDA Margin-191.33%+19.8%
- Operating Margin-194.04%+19.6%
- Net Margin-210.54%+16.2%
- ROE-249.28%+22.1%
INSM Key Insights
Insmed Incorporated (INSM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 29.8%
✗Weaknesses
- ✗Profits declining 34.1% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 10 (bottom 10%)
- ✗Shares diluted 30.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 27.7x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when INSM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
INSM Price & Volume
Insmed Incorporated (INSM) stock price & volume — 10-year historical chart
Loading chart...
INSM Growth Metrics
Insmed Incorporated (INSM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years29.83%
3 Years35.2%
TTM115.09%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.83%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.36%
Return on Capital
10 Years-53.03%
5 Years-52.31%
3 Years-61.35%
Last Year-66.8%
INSM Recent Earnings
Insmed Incorporated (INSM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.76+21.1%
$0.96
Rev
$306M+1.7%
$301M
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$1.54-43.9%
$1.07
Rev
$264M+14.1%
$231M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$1.75-31.6%
$1.33
Rev
$142M+23.3%
$115M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$1.70-30.8%
$1.30
Rev
$107M+3.2%
$104M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.76vs $0.96+21.1% | $306Mvs $301M+1.7% |
| Q1 2026 | Feb 19, 2026 | $1.54vs $1.07-43.9% | $264Mvs $231M+14.1% |
| Q4 2025 | Oct 30, 2025 | $1.75vs $1.33-31.6% | $142Mvs $115M+23.3% |
| Q3 2025 | Aug 7, 2025 | $1.70vs $1.30-30.8% | $107Mvs $104M+3.2% |
Based on last 12 quarters of dataView full earnings history →
INSM Peer Comparison
Insmed Incorporated (INSM) competitors in Commercial Specialty Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 ALNY | 37.1B | 278.09 | 119.35 | 65.19% | 13.46% | 98.29% | 1.62 | |
 BMRN | 10.52B | 54.69 | 30.38 | 12.87% | 8.29% | 4.41% | 0.11 | |
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 |
Compare INSM vs Peers
Insmed Incorporated (INSM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
INSM Income Statement
Insmed Incorporated (INSM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 9.84M | 136.47M | 164.41M | 188.46M | 245.36M | 305.21M | 363.71M | 606.42M | 819.56M |
Revenue Growth % | - | - | 1287.56% | 20.48% | 14.63% | 30.19% | 24.39% | 19.17% | 66.73% | 115.09% |
Cost of Goods Sold | 2.9M | 2.42M | 24.21M | 39.87M | 44.15M | 55.13M | 65.57M | 85.74M | 124.88M | 151.16M |
COGS % of Revenue | - | 24.64% | 17.74% | 24.25% | 23.43% | 22.47% | 21.48% | 23.57% | 20.59% | - |
Gross Profit | -2.9M▲ 0% | 7.41M▲ 355.5% | 112.25M▲ 1414.5% | 124.54M▲ 10.9% | 144.31M▲ 15.9% | 190.23M▲ 31.8% | 239.63M▲ 26.0% | 277.96M▲ 16.0% | 481.55M▲ 73.2% | 668.4M▲ 0% |
Gross Margin % | - | 75.36% | 82.26% | 75.75% | 76.57% | 77.53% | 78.52% | 76.43% | 79.41% | 81.56% |
Gross Profit Growth % | -18.99% | 355.5% | 1414.5% | 10.94% | 15.87% | 31.82% | 25.97% | 16% | 73.24% | - |
Operating Expenses | 188.92M | 314.75M | 347.5M | 389.77M | 519.4M | 647.55M | 949.26M | 1.16B | 1.66B | 1.8B |
OpEx % of Revenue | - | 3200.31% | 254.64% | 237.07% | 275.6% | 263.92% | 311.02% | 317.9% | 273.45% | - |
Selling, General & Admin | 79.17M | 168.22M | 210.8M | 203.61M | 234.27M | 265.78M | 344.5M | 461.12M | 701.17M | 800.88M |
SG&A % of Revenue | - | 1710.4% | 154.47% | 123.84% | 124.31% | 108.33% | 112.87% | 126.78% | 115.62% | - |
Research & Development | 109.75M | 145.28M | 131.71M | 181.16M | 272.74M | 397.52M | 571.01M | 598.37M | 771.09M | 828M |
R&D % of Revenue | - | 1477.2% | 96.51% | 110.18% | 144.72% | 162.02% | 187.09% | 164.52% | 127.15% | - |
Other Operating Expenses | 300K | 1.25M | 4.99M | 5M | 12.39M | -15.75M | 33.75M | 96.73M | 186.02M | 3M |
Operating Income | -188.92M▲ 0% | -307.34M▼ 62.7% | -235.25M▲ 23.5% | -265.23M▼ 12.7% | -375.09M▼ 41.4% | -457.32M▼ 21.9% | -709.63M▼ 55.2% | -878.25M▼ 23.8% | -1.18B▼ 34.0% | -1.13B▲ 0% |
Operating Margin % | - | -3124.94% | -172.38% | -161.32% | -199.03% | -186.39% | -232.51% | -241.47% | -194.04% | -137.74% |
Operating Income Growth % | -8.95% | -62.68% | 23.46% | -12.75% | -41.42% | -21.92% | -55.17% | -23.76% | -33.99% | - |
EBITDA | -186.02M | -302.51M | -225.06M | -251.08M | -360.91M | -446.99M | -699.05M | -867.24M | -1.16B | -1.11B |
EBITDA Margin % | - | -3075.87% | -164.92% | -152.71% | -191.5% | -182.18% | -229.04% | -238.44% | -191.33% | -135.42% |
EBITDA Growth % | -8.81% | -62.62% | 25.6% | -11.56% | -43.74% | -23.85% | -56.39% | -24.06% | -33.79% | -14.47% |
D&A (Non-Cash Add-back) | 2.9M | 4.83M | 10.18M | 14.15M | 14.18M | 10.33M | 10.58M | 11.01M | 16.45M | 19M |
EBIT | -187M | -300M | -227.25M | -264.52M | -397.83M | -457.7M | -670.76M | -829.81M | -1.19B | -1.16B |
Net Interest Income | -4.3M | -15.13M | -17.78M | -27.86M | -40.3M | -15.37M | -39.56M | -31.61M | -23.14M | -37.38M |
Interest Income | 1.62M | 10.34M | 9.92M | 1.7M | 174K | 11.08M | 42.13M | 53.31M | 60.66M | 43.55M |
Interest Expense | 5.92M | 25.47M | 27.7M | 29.56M | 40.47M | 26.45M | 81.69M | 84.91M | 83.8M | 80.93M |
Other Income/Expense | -4M | -16.74M | -18.32M | -27.46M | -61.32M | -22.83M | -37.39M | -31.81M | -95.02M | -49.31M |
Pretax Income | -192.92M▲ 0% | -324.08M▼ 68.0% | -253.56M▲ 21.8% | -292.69M▼ 15.4% | -436.41M▼ 49.1% | -480.15M▼ 10.0% | -747.01M▼ 55.6% | -910.07M▼ 21.8% | -1.27B▼ 39.7% | -1.18B▲ 0% |
Pretax Margin % | - | -3295.13% | -185.8% | -178.02% | -231.57% | -195.69% | -244.76% | -250.22% | -209.71% | -143.76% |
Income Tax | -272K | 201K | 777K | 1.4M | -1.76M | 1.38M | 2.56M | 3.71M | 5.03M | 5.58M |
Effective Tax Rate % | 0.14% | -0.06% | -0.31% | -0.48% | 0.4% | -0.29% | -0.34% | -0.41% | -0.4% | -0.47% |
Net Income | -192.65M▲ 0% | -324.28M▼ 68.3% | -254.34M▲ 21.6% | -294.09M▼ 15.6% | -434.65M▼ 47.8% | -481.53M▼ 10.8% | -749.57M▼ 55.7% | -913.77M▼ 21.9% | -1.28B▼ 39.7% | -1.18B▲ 0% |
Net Margin % | - | -3297.17% | -186.37% | -178.87% | -230.63% | -196.26% | -245.59% | -251.24% | -210.54% | -144.44% |
Net Income Growth % | -9.29% | -68.33% | 21.57% | -15.63% | -47.8% | -10.79% | -55.66% | -21.91% | -39.73% | -16.83% |
Net Income (Continuing) | -192.65M | -324.28M | -254.34M | -294.09M | -434.65M | -481.53M | -749.57M | -913.77M | -1.28B | -1.18B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.89▲ 0% | -4.22▼ 46.0% | -3.01▲ 28.7% | -3.01▲ 0.0% | -3.88▼ 28.9% | -3.91▼ 0.8% | -5.34▼ 36.6% | -5.57▼ 4.3% | -6.41▼ 15.1% | -5.49▲ 0% |
EPS Growth % | -1.4% | -46.02% | 28.67% | 0% | -28.9% | -0.77% | -36.57% | -4.31% | -15.08% | 3.36% |
EPS (Basic) | -2.89 | -4.22 | -3.01 | -3.01 | -3.88 | -3.91 | -5.34 | -5.57 | -6.41 | - |
Diluted Shares Outstanding | 66.58M | 76.89M | 84.56M | 97.61M | 112.11M | 123.03M | 140.43M | 164.04M | 213.64M | 215.47M |
Basic Shares Outstanding | 66.58M | 76.84M | 84.56M | 97.61M | 112.11M | 123.03M | 140.43M | 164.04M | 213.64M | 215.47M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
INSM Balance Sheet
Insmed Incorporated (INSM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 389.44M | 518.95M | 555.19M | 622.89M | 837.04M | 1.27B | 929.06M | 1.62B | 1.79B | 1.61B |
Cash & Short-Term Investments | 381.17M | 495.07M | 487.43M | 532.76M | 716.78M | 1.15B | 780.45M | 1.43B | 1.43B | 1.22B |
Cash Only | 381.17M | 495.07M | 487.43M | 532.76M | 716.78M | 1.07B | 482.37M | 555.03M | 510.44M | 582.19M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 74.24M | 298.07M | 878.8M | 919.6M | 641.33M |
Accounts Receivable | 0 | 5.51M | 19.23M | 16.56M | 24.35M | 29.71M | 41.19M | 52.01M | 140.86M | 178.56M |
Days Sales Outstanding | - | 204.67 | 51.44 | 36.77 | 47.16 | 44.2 | 49.26 | 52.2 | 84.78 | 48.96 |
Inventory | 0 | 7.03M | 28.31M | 49.59M | 67.01M | 69.92M | 83.25M | 98.58M | 132.07M | 132.91M |
Days Inventory Outstanding | - | 1.06K | 426.82 | 453.98 | 553.96 | 462.97 | 463.38 | 419.64 | 386.02 | 297.94 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 25.47M | 24.18M | 37.24M | 91.24M | 78.19M |
Total Non-Current Assets | 72.6M | 85.61M | 187.1M | 173.26M | 406.47M | 383.05M | 400.77M | 403.57M | 470.35M | 462.69M |
Property, Plant & Equipment | 12.43M | 22.64M | 113.11M | 97.23M | 95.52M | 102.08M | 104.39M | 115.58M | 139.21M | 131.73M |
Fixed Asset Turnover | - | 0.43x | 1.21x | 1.69x | 1.97x | 2.40x | 2.92x | 3.15x | 4.36x | 6.49x |
Goodwill | 0 | 0 | 0 | 0 | 136.11M | 136.11M | 136.11M | 136.11M | 136.11M | 136.11M |
Intangible Assets | 58.2M | 58.67M | 53.68M | 49.26M | 73.81M | 68.76M | 63.7M | 58.65M | 97.65M | 95.57M |
Long-Term Investments | 0 | 0 | 0 | 0 | 50.04M | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 1.97M | 4.3M | 20.31M | 26.77M | 50.99M | 76.1M | 96.57M | 93.23M | 97.38M | 99.28M |
Total Assets | 462.05M▲ 0% | 604.56M▲ 30.8% | 742.3M▲ 22.8% | 796.15M▲ 7.3% | 1.24B▲ 56.2% | 1.66B▲ 33.2% | 1.33B▼ 19.7% | 2.03B▲ 52.3% | 2.26B▲ 11.8% | 2.08B▲ 0% |
Asset Turnover | - | 0.02x | 0.18x | 0.21x | 0.15x | 0.15x | 0.23x | 0.18x | 0.27x | 0.36x |
Asset Growth % | 94.17% | 30.84% | 22.78% | 7.26% | 56.19% | 33.21% | -19.72% | 52.29% | 11.82% | 78.96% |
Total Current Liabilities | 44.66M | 79.73M | 85.24M | 118.81M | 135.17M | 190.24M | 225.63M | 297.53M | 468.87M | 361.01M |
Accounts Payable | 14.67M | 17.74M | 13.18M | 42.85M | 35.78M | 50.46M | 65.39M | 73.03M | 79.91M | 73.38M |
Days Payables Outstanding | 1.85K | 2.67K | 198.75 | 392.29 | 295.82 | 334.11 | 364 | 310.9 | 233.56 | 185.28 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.5M | 19.26M | 14.43M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12.84M | 23.74M | 19.42M | 25.59M | 33.46M | 42.74M | 55.63M | 127.69M | 258.19M | 227.22M |
Current Ratio | 8.72x | 6.51x | 6.51x | 5.24x | 6.19x | 6.69x | 4.12x | 5.45x | 3.83x | 4.47x |
Quick Ratio | 8.72x | 6.42x | 6.18x | 4.83x | 5.70x | 6.33x | 3.75x | 5.12x | 3.54x | 4.10x |
Cash Conversion Cycle | - | -1.41K | 279.51 | 98.46 | 305.3 | 173.06 | 148.64 | 160.94 | 237.24 | 161.61 |
Total Non-Current Liabilities | 56.33M | 316.56M | 395.38M | 401.46M | 697.87M | 1.38B | 1.44B | 1.44B | 1.06B | 1.01B |
Long-Term Debt | 55.57M | 316.56M | 335.94M | 356.32M | 566.59M | 1.13B | 1.16B | 1.26B | 716M | 704.35M |
Capital Lease Obligations | 0 | 0 | 48.84M | 35.97M | 35.54M | 44.49M | 38.04M | 33.18M | 32.89M | 122.07M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 765K | 0 | 10.61M | 9.18M | 95.74M | 208.5M | 242.78M | 144.7M | 307.81M | 275.99M |
Total Liabilities | 100.99M | 396.29M | 480.63M | 520.27M | 833.04M | 1.57B | 1.66B | 1.74B | 1.53B | 1.37B |
Total Debt | 55.57M | 316.56M | 397.04M | 404.84M | 612.27M | 1.18B | 1.2B | 1.31B | 768.16M | 748.43M |
Net Debt | -325.6M | -178.51M | -90.39M | -127.91M | -104.51M | 103.83M | 721.62M | 759.09M | 257.71M | 166.25M |
Debt / Equity | 0.15x | 1.52x | 1.52x | 1.47x | 1.49x | 13.39x | - | 4.60x | 1.04x | 1.06x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.67x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.15x |
Interest Coverage | -31.56x | -11.78x | -8.20x | -8.95x | -9.83x | -17.31x | -8.21x | -9.77x | -14.18x | -14.31x |
Total Equity | 361.06M▲ 0% | 208.27M▼ 42.3% | 261.67M▲ 25.6% | 275.88M▲ 5.4% | 410.47M▲ 48.8% | 87.95M▼ 78.6% | -331.92M▼ 477.4% | 285.38M▲ 186.0% | 738.98M▲ 158.9% | 704.85M▲ 0% |
Equity Growth % | 133.72% | -42.32% | 25.64% | 5.43% | 48.78% | -78.57% | -477.4% | 185.98% | 158.95% | 3984.85% |
Book Value per Share | 5.42 | 2.71 | 3.09 | 2.83 | 3.66 | 0.71 | -2.36 | 1.74 | 3.46 | 3.27 |
Total Shareholders' Equity | 361.06M | 208.27M | 261.67M | 275.88M | 410.47M | 87.95M | -331.92M | 285.38M | 738.98M | 704.85M |
Common Stock | 766K | 773K | 897K | 1.03M | 1.19M | 1.36M | 1.48M | 1.79M | 2.14M | 2.17M |
Retained Earnings | -957.88M | -1.28B | -1.54B | -1.83B | -2.27B | -2.7B | -3.45B | -4.36B | -5.64B | -5.8B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -3K | -9K | -10K | 193K | 968K | 756K | -745K | -2.29M | 1.46M | 4K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
INSM Cash Flow Statement
Insmed Incorporated (INSM) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -159.62M | -257.98M | -250.65M | -219.35M | -363.3M | -400.44M | -536.25M | -683.88M | -935.01M | -895.66M |
Operating CF Margin % | - | -2623.05% | -183.67% | -133.41% | -192.77% | -163.21% | -175.7% | -188.03% | -154.19% | - |
Operating CF Growth % | -8.8% | -61.62% | 2.84% | 12.49% | -65.63% | -10.22% | -33.91% | -27.53% | -36.72% | -99.99% |
Net Income | -192.65M | -324.28M | -254.34M | -294.09M | -434.65M | -481.53M | -749.57M | -913.77M | -1.28B | -1.18B |
Depreciation & Amortization | 2.9M | 4.83M | 10.18M | 14.15M | 14.18M | 10.33M | 10.58M | 11.01M | 16.45M | 18.32M |
Stock-Based Compensation | 18.07M | 26.24M | 26.97M | 36.16M | 46.02M | 57.69M | 74.78M | 96.83M | 152.71M | 120.16M |
Deferred Taxes | 0 | 2.21M | 0 | 0 | 17.69M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 776K | 17.29M | 29.5M | 27.39M | 52.04M | 6.5M | 167.18M | 125.22M | 252.9M | 228.03M |
Working Capital Changes | 11.28M | 15.74M | -62.97M | -2.95M | -58.58M | 6.58M | -39.22M | -3.18M | -80.3M | -78.42M |
Change in Receivables | 0 | -5.51M | -13.72M | 2.67M | -8.12M | -6.42M | -11.96M | -12.93M | -88.31M | -131.86M |
Change in Inventory | 0 | -7.03M | -21.28M | -21.18M | -17.46M | -1.71M | -13.61M | -17.04M | -31.52M | -32.38M |
Change in Payables | 3.6M | 3.87M | -4.97M | 29.82M | -7.58M | 50.01M | 15.15M | 44.59M | 100.07M | 127.69M |
Cash from Investing | -3M | -14.81M | -42.27M | -6.82M | -64.28M | -34.58M | -223.6M | -583.17M | -64.58M | 120.53M |
Capital Expenditures | -3M | -14.81M | -42.27M | -6.82M | -7.29M | -9.88M | -13.29M | -21.92M | -32.56M | -55.97M |
CapEx % of Revenue | - | 150.63% | 30.97% | 4.15% | 3.87% | 4.03% | 4.35% | 6.03% | 5.37% | 6.83% |
Acquisitions | 0 | 0 | 0 | 0 | -6.7M | 24.71M | 3.42M | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | -57M | -24.71M | 0 | 0 | -30M | -15M |
Cash from Financing | 381.09M | 386.74M | 285.28M | 271M | 612.55M | 793.27M | 168.44M | 1.34B | 954.07M | 954.59M |
Debt Issued (Net) | 0 | 392.17M | 0 | 769K | 336.34M | 349.4M | -1.22M | 147.39M | -4.93M | -5.02M |
Equity Issued (Net) | 377.66M | 8.81M | 261.07M | 245.87M | 269.89M | 292.15M | 152.47M | 1.08B | 959M | 959.61M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 3.43M | -14.24M | 24.2M | 25.14M | 6.32M | 151.72M | 17.18M | 109.51M | 0 | 0 |
Net Change in Cash | 218.57M▲ 0% | 113.91M▼ 47.9% | -7.64M▼ 106.7% | 45.33M▲ 693.1% | 184.03M▲ 306.0% | 357.25M▲ 94.1% | -591.66M▼ 265.6% | 72.66M▲ 112.3% | -44.59M▼ 161.4% | 178.94M▲ 0% |
Free Cash Flow | -162.62M▲ 0% | -272.79M▼ 67.7% | -292.92M▼ 7.4% | -226.17M▲ 22.8% | -370.59M▼ 63.9% | -410.32M▼ 10.7% | -549.53M▼ 33.9% | -705.8M▼ 28.4% | -967.58M▼ 37.1% | -951.63M▲ 0% |
FCF Margin % | - | -2773.68% | -214.64% | -137.56% | -196.64% | -167.23% | -180.05% | -194.06% | -159.55% | -116.11% |
FCF Growth % | -7.76% | -67.75% | -7.38% | 22.79% | -63.86% | -10.72% | -33.93% | -28.44% | -37.09% | -20.57% |
FCF per Share | -2.44 | -3.55 | -3.46 | -2.32 | -3.31 | -3.33 | -3.91 | -4.30 | -4.53 | -4.42 |
FCF Conversion (FCF/Net Income) | 0.83x | 0.80x | 0.99x | 0.75x | 0.84x | 0.83x | 0.72x | 0.75x | 0.73x | 0.80x |
Interest Paid | 5.17M | 6.29M | 7.88M | 9.19M | 10.89M | 10.16M | 35.79M | 40.57M | 0 | 13.27M |
Taxes Paid | 166K | 154K | 339K | 814K | 1.56M | 1.72M | 1.96M | 2.5M | 0 | 677K |
INSM Key Ratios
Insmed Incorporated (INSM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -74.74% | -113.92% | -108.24% | -109.42% | -126.66% | -193.22% | - | -320.2% | -249.28% | -130.11% |
Return on Invested Capital (ROIC) | -344.98% | -706.93% | -175.53% | -124.62% | -123.95% | -137.82% | -183.06% | -91.86% | -86.48% | -86.12% |
Gross Margin | - | 75.36% | 82.26% | 75.75% | 76.57% | 77.53% | 78.52% | 76.43% | 79.41% | 81.56% |
Net Margin | - | -3297.17% | -186.37% | -178.87% | -230.63% | -196.26% | -245.59% | -251.24% | -210.54% | -144.44% |
Debt / Equity | 0.15x | 1.52x | 1.52x | 1.47x | 1.49x | 13.39x | - | 4.60x | 1.04x | 1.06x |
Interest Coverage | -31.56x | -11.78x | -8.20x | -8.95x | -9.83x | -17.31x | -8.21x | -9.77x | -14.18x | -14.31x |
FCF Conversion | 0.83x | 0.80x | 0.99x | 0.75x | 0.84x | 0.83x | 0.72x | 0.75x | 0.73x | 0.80x |
Revenue Growth | - | - | 1287.56% | 20.48% | 14.63% | 30.19% | 24.39% | 19.17% | 66.73% | 115.09% |
Related:INSM Dividend History·INSM Revenue History·INSM Price History·INSM P/E History·INSM Financial Ratios·INSM Institutional Holders
INSM SEC Filings & Documents
Insmed Incorporated (INSM) SEC filings — annual & quarterly reports (10-K, 10-Q)
INSM Frequently Asked Questions
Insmed Incorporated (INSM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Insmed Incorporated (INSM) reported $819.6M in revenue for fiscal year 2025. This represents a 81956300% increase from $0.0M in 1999.
Insmed Incorporated (INSM) grew revenue by 66.7% over the past year. This is strong growth.
Insmed Incorporated (INSM) reported a net loss of $1.18B for fiscal year 2025.
Dividend & Returns
Insmed Incorporated (INSM) has a return on equity (ROE) of -249.3%. Negative ROE indicates the company is unprofitable.
Insmed Incorporated (INSM) had negative free cash flow of $951.6M in fiscal year 2025, likely due to heavy capital investments.